Central nervous system adverse effects with efavirenz: case report and review.
Efavirenz is a nonnucleoside reverse transcriptase inhibitor that can be given with other antiretroviral agents for the treatment of human immunodeficiency virus infection. A 47-year-old man with acquired immunodeficiency syndrome developed severe depression and suicidal ideation necessitating psychiatric hospitalization and antidepressant therapy. The symptoms occurred in temporal relation to the introduction of efavirenz into his highly active antiretroviral therapy regimen. Similar serious psychiatric adverse effects have been associated with this agent. Clinicians should monitor for central nervous system adverse effects in all patients taking efavirenz.
Puzantian
Talia
T
Department of Psychiatry, San Francisco General Hospital, California 94110, USA.
D015526:AIDS Dementia Complex / Q000139:chemically induced / Q000523:psychology; D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D048588:Benzoxazines; D003521:Cyclopropanes; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced / Q000523:psychology; D008875:Middle Aged; D010078:Oxazines / Q000009:adverse effects*
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; C098320:efavirenz